Russ Conroy

Data from the phase 3 Precision-T trial support the FDA approval of allogeneic regulatory T-cell–based immunotherapy.

Two teams of lung cancer experts face off to determine the optimal first-line treatment regimen in EGFR-mutated metastatic NSCLC.

Investigators will share detailed results from the phase 3 SigVie-002 trial assessing sigvotatug vedotin in NSCLC at a future medical meeting.

Data from the SPEARHEAD-1 study support the full FDA approval of afami-cel in this synovial sarcoma population.

This year’s EHA Congress saw potential advances across multiple myeloma, leukemia, lymphoma, and other hematologic malignancy populations.

Data from a phase 2 trial support further clinical development of AK117 in previously untreated acute myeloid leukemia.

Data from a phase 1/2 trial show durable disease control with belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.

Phase 1 data support arlo-cel as a potentially effective early-line treatment option for those with relapsed/refractory multiple myeloma.

MRD responses appeared to be more favorable with the use of blinatumomab among pediatric patients with high-risk B-cell acute lymphoblastic leukemia.

Data from the MAXILUS study affirm the importance of early treatment initiation among those with lower-risk myelodysplastic syndrome.

High rates of MRD negativity were observed with a combination of carfilzomib, lenalidomide, daratumumab, and dexamethasone in the ASCENT trial.

Investigators observed no new safety signals with lurbinectedin alone or in combination with irinotecan in the phase 3 LAGOON trial.

Findings from the ASC4FIRST trial show that asciminib is meeting high expectations as a frontline therapy in chronic myeloid leukemia in chronic phase.

Data from the CASSIOPEIA trial showed that more than half of patients with high-risk disease achieved 5-year disease-free survival with tisagenlecleucel.

A recommendation from the external data monitoring committee led to the discontinuation of the phase 3 KEYNOTE D46/EVOKE-03 study.

Data from the phase 3 DeLLphi-304 trial support the European Commission’s approval of tarlatamab in extensive-stage small cell lung cancer.

Cancer-related survival was similar among patients with PD-L1–positive or PD-L1–negative NSCLC who received durvalumab.

Real-world data support prospective evaluation of a frontline venetoclax-based regimen in the second line and beyond.

Retrospective data also showed that immune-related toxicities were more common with BCMA CAR T-cell therapy compared with teclistamab.

The ivonescimab-based regimen appeared effective in both platinum-sensitive and platinum-resistant cohorts in a phase 2 study.

More than 90% of patients achieved a composite complete response to azacitidine plus venetoclax and ivosidenib in a phase 1b/2 trial.

The nilotinib tablets may support patients who have difficulty swallowing while offering flexibility to take treatment with or without water.

The role of adjuvant immunotherapy remains unclear in this NSCLC population following data from the phase 3 ALCHEMIST trial.

A matching-adjusted indirect comparison highlighted linvoseltamab as a potentially effective treatment option for those with triple-class–exposed disease.

No grade 3 or higher CRS or ICANS events occurred among patients who received prophylactic tocilizumab before outpatient bispecific antibody treatment.

Data from the phase 2 ERASMM trial support further evaluation of elranatamab among patients with high-risk smoldering multiple myeloma.

Presentations at the 2026 ASCO Annual Meeting may reveal key advances in the use of different bispecific antibodies and CELMoDs in multiple myeloma care.

The FDA has assigned a Prescription Drug User Fee Act date of November 27, 2026, for neladalkib in this ALK-positive non–small cell lung cancer population.

Data from the phase 1/2 CADENZA trial support the approval of pivekimab sunirine for patients with blastic plasmacytoid dendritic cell neoplasms.

Developers intend to submit a supplemental new drug application for toripalimab/chemotherapy in resectable stage II or III NSCLC.